PATENT EXPIRY
Oppo, Nokia seek withdrawal of patent infringement case from Delhi High Court
Nokia Technologies and Guangdong OPPO Mobile Telecommunications Corp informed the Delhi High Court on Tuesday of their intention to withdraw their lawsuits, including Nokia's patent infringement claim. They cited a resolved dispute and a confidential litigation settlement reached last month.
Oppo, Nokia resolve global patent dispute with cross-license agreement
The Finnish tech company owns over 6000 patent families declared essential to 5G connectivity in smartphones. Out of them, 30 patents covering a mix of cellular standards, connectivity, user interface and security, were the bone of contention in the licensing disputes. Nokia licenses these patents to smartphone brands on fair, reasonable, and non-discriminatory (FRAND) terms.
Pharma cos can supply generic Bedaquiline to other countries
Multinational pharmaceutical company Johnson & Johnson (J&J) has announced that it will not enforce secondary patents for its anti-TB drug Bedaquiline in low and middle income countries. This means that Indian pharmaceutical companies will be able to supply generic versions of the drug without the fear of litigation.
Key patent application by J&J for TB drug rejected
The company had filed a patent for Fumarate salt of bedaquiline in 2008 to extend its patent till the end of 2027. It was under review by the patent office. The strategy is called patent evergreening used by companies to keep the prices high as it would keep the affordably priced generic versions of the drug out of the market.
Nokia signs 5G patent agreement with Samsung
Nordic rival Ericsson last year also reached an agreement on 5G patents with Samsung, ending a dispute that hit its quarterly revenue. Nokia's patent portfolio is made of around 20,000 patent families, including over 4,500 patent families declared essential to 5G.
Johnson & Johnson tuberculosis drug's final patent hearing set for today
The latest secondary patent application, if granted, allows J&J to extend the monopoly on the drug used for treatment of drug resistant (DR-TB) till December 2027.
- Go To Page 1
HC reserves order on Natco's plea over patent for Novartis drug
Natco has argued before Justice C Hari Shankar against the grant of patent by IPO to the pharmaceutical composition comprising combination of sacubitril + valsartan as a sodium salt complex of the Vymada.
How to go about patent filing in India: All you need to know
The fundamental idea is to safeguard the inventions that are created and therefore, encourage more developments.
High court order on diabetes drug patent may reduce prices
The cost for treating diabetes is expected to come down with the Delhi high court having dismissed an appeal by AstraZeneca, which had sought the restraining of the generic versions of a blockbuster drug.
Ericsson files patent royalty lawsuit against Samsung in U.S.
Delayed royalty payments from unlicensed periods and potential costs of litigation may impact Ericsson's operating income by 1 billion Swedish crowns ($118.70 million) to 1.5 billion per quarter beginning in the first quarter 2021, the company said.
DIPP floats draft patent rules
The department has sought views of stakeholders on the draft rules till January.
Agrochemical firms spot a 'generic' promise in patent expiry in sector
Falling commodity prices have been driving the US and Latin American farmers to shift to generic agrochemicals from expensive patented products over the past few years.
Patents expiry to boost agrochemical firms' sales, profits
Industry experts feel the Indian agro-chemicals sector may witness an annual growth of 15-20 per cent following patents expiry from currently around 8-9 per cent.
Delhi HC Upholds BMS' Patent for Cancer Drug Dasatinib
The Delhi High Court has upheld the patent of US-based BMS for Dasatinib, dashing the hopes of a local company to sell a generic version of the cancer drug
Delhi High Court upholds BMS’ patent for cancer drug Dasatinib
The Indian Patent Office had in 2013 rejected the company’s demand for a compulsory licence as it did not follow the procedures for obtaining a voluntary licence.
Government may negotiate price of patented drugs before market entry
The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India.
Claris confirms patent challenge for generic Propofol in US
The company has filed a an ANDA for Propofol injection in strength of 10 mg/ml with the US Food and Drug Administration (FDA).
3D printing may turn cheap as patents expire
A bunch of 3D printing patents expiring this year are likely to open up opportunities for Indian entrepreneurs to build more efficient.
3D printing may turn cheap as patents expire
Many are eagerly waiting for the patents to expire later this year. The market will likely see another round of hectic innovations.
Sanofi files cases against Glenmark on patent infringement
Sanofi had submitted its application to seek US Food and Drug Administration's (USFDA's) approval for its generic version of the drug on January 24, 2014.
Glenmark faces patent infringement suit in US
Glenmark Pharmaceuticals has been slapped with a patent infringement case by US-based Cephalon Inc to sell generic version of Treanda.
Dr Reddy's Laboratories will infringe on Lunesta's patent: US court of appeal
The United States Court of Appeals for the Federal Circuit has ruled that Dr Reddy's Laboratories Ltd will (rpt will) infringe on the patent of Sunovion Pharmaceuticals blockbuster drug Lunesta.
Sun Pharma gets FDA nod for generic version of Januvia
This comes as a surprise as Sun has partnered the US based MSD in the domestic market to sue Glenmark for the patent infringement on the same drug.
India eyes $40 billion global generic market; patents held by MNCs to expire in over 3 years
Analysts say the timing to promote Indian generics globally is just right as the next three years will be crucial in terms of opportunity.
Patent expiries: Dr Reddy's, Lupin to foray into specialty pharma, Aurobindo Pharma to focus on services
India's top pharmaceutical companies are preparing for life after high revenues from expiring patents drops off at the end of this year.
US doublespeak on patent waiver bared
The country has resorted to its liberal use while objecting to concession on cancer drug by India.
Drug patents expiry to give generic pharma market shot in arm
The patent expiry of several major 'blockbuster' drugs, coupled with other factors, will fuel growth of global generic pharmaceuticals market by 2017, research firm Frost & Sullivan said.
Alembic Pharmaceuticals soars on patent settlement case with Novartis
Shares of Alembic Pharma surged by over 4% after the co said it along with Breckenridge Pharma Inc, USA has settled a patent case with Novartis.
Patent expiry may open up $90-bn market for Dr Reddy’s Laboratories
Dr Reddy’s Laboratories may be the biggest beneficiary among Indian generic-drug makers as $157-billion worth medicines, including Eli Lilly & Co’s Zyprexa, lose patent protection within five years, according to HDFC Securities.
Load More
